← Syndax Pharmaceuticals Inc
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Available to Common Stockholders, Basic | ($47.1m) |
($60.8m)
-29.17%
|
($74.0m)
-21.64%
|
($56.0m)
+24.22%
|
($77.1m)
-37.50%
|
$24.9m
+132.34%
|
($149.3m)
-699.13%
|
($209.4m)
-40.19%
|
($318.8m)
-52.25%
|
($285.4m)
+10.46%
|
— | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($44.5m) | ($60.8m) | ($74.0m) | ($56.0m) | ($73.2m) | $24.9m | ($149.3m) | ($209.4m) | ($318.8m) | ($285.4m) | — | |
| Depreciation | $89k | $76k | $78k | $92k | $89k | $43k | $33.0m | $12.0m | $8.0m | $6.0m | $15k | |
| Amortization of Debt Issuance Costs | — | — | — | — | — | — | $0 | $0 | $30k | $228k | — | |
| Amortization Of Securities | — | — | — | — | — | — | ($3.4m) | ($14.8m) | ($13.5m) | ($10.8m) | ($5.5m) | |
| Depreciation Amortization Depletion | — | — | — | — | — | — | $33k | $12k | $8k | $6k | $15k | |
| Share-based Payment Arrangement, Noncash Expense | $4.7m | $5.5m | $6.2m | $6.0m | $9.1m | $13.3m | $16.0m | $31.0m | $43.0m | $47.5m | $49.4m | |
| Share-based Payment Arrangement, Expense | $4.7m | $5.5m | $6.2m | $6.0m | $9.1m | $13.3m | $16.0m | $31.0m | $43.0m | $47.5m | $49.4m | |
| Nonoperating Income (Expense) | ($706k) | $1.2m | $1.9m | $1.5m | ($1.7m) | ($1.3m) | $2.4m | $20.6m | $20.9m | ($12.3m) | — | |
| Other Nonoperating Income (Expense) | $41k | ($269k) | ($27k) | ($79k) | ($219k) | $202k | ($316k) | ($361k) | ($247k) | ($1.3m) | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Change In Working Capital | — | — | — | — | — | — | $1.7m | $31.9m | $13.3m | ($79.3m) | ($49.4m) | |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | — | — | $7.6m | $30.4m | ($71.3m) | |
| Change In Receivables | — | — | — | — | — | — | $0 | $10.7m | $762k | ($79.8m) | ($71.3m) | |
| Changes In Account Receivables | — | — | — | — | — | — | $0 | $0 | ($7.6m) | ($30.4m) | ($71.3m) | |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | — | — | $366k | $32.1m | ($15.2m) | |
| Change In Inventory | — | — | — | — | — | — | $0 | $0 | ($366k) | ($32.1m) | ($15.2m) | |
| Increase (Decrease) in Accounts Payable | $923k | ($194k) | ($792k) | $4.7m | ($2.7m) | $2.2m | ($1.3m) | $5.6m | $1.7m | $5.0m | ($12.5m) | |
| Change In Payables And Accrued Expense | — | — | — | — | — | — | $8.1m | $20.5m | $20.8m | $47.1m | ($12.5m) | |
| Change In Accrued Expense | — | — | — | — | — | — | $9.4m | $14.9m | $19.1m | $42.2m | $17.2m | |
| Change In Other Current Assets | — | — | — | — | — | — | $0 | $0 | $463k | $0 | $0 | |
| Net Cash Provided by (Used in) Operating Activities | ($35.2m) |
($47.4m)
-34.74%
|
($68.5m)
-44.67%
|
($50.6m)
+26.15%
|
($71.3m)
-40.80%
|
$29.1m
+140.88%
|
($133.7m)
-558.88%
|
($160.6m)
-20.14%
|
($274.9m)
-71.17%
|
($323.0m)
-17.49%
|
($220.6m)
+31.69%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $261k | $84k | $187k | — | $0 | $129k | $0 | $0 | $0 | $187k | ($187k) | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Marketable Securities, Unrealized Gain (Loss) | $28k | — | — | — | — | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | ($18.4m) | ($17.0m) | $51.4m | $12.8m | ($142.5m) | ($40.9m) | ($186.2m) | $117.6m | ($219.8m) | $290.0m | $175.5m | |
| Cash flows from financing activities: | ||||||||||||
| Issuance Of Debt | — | — | — | — | — | $0 | $0 | — | — | — | $0 | |
| Long Term Debt Issuance | — | — | — | — | — | $0 | $0 | — | — | — | $0 | |
| Long Term Debt Payments | — | — | — | — | — | $0 | ($21.0m) | $0 | $0 | — | $0 | |
| Net Issuance Payments Of Debt | — | — | — | — | — | $0 | ($21.0m) | $0 | $0 | — | $0 | |
| Net Long Term Debt Issuance | — | — | — | — | — | $0 | ($21.0m) | $0 | $0 | — | $0 | |
| Repayment Of Debt | — | — | — | — | — | $0 | ($21.0m) | $0 | $0 | — | $0 | |
| Common Stock Issuance | — | — | — | — | — | — | $181.4m | $258.1m | $0 | $0 | $0 | |
| Issuance Of Capital Stock | — | — | — | — | — | — | $181.4m | $258.1m | $0 | $0 | $0 | |
| Proceeds from (Payments for) Other Financing Activities | ($4k) | — | $8k | — | $1k | — | — | — | — | — | — | |
| Net Other Financing Charges | — | — | — | — | — | $576k | — | — | $343.7m | — | $343.7m | |
| Net Cash Provided by (Used in) Financing Activities | $54.2m |
$75.7m
+39.70%
|
$15.7m
-79.23%
|
$28.6m
+81.64%
|
$304.4m
+965.54%
|
$118.5m
-61.09%
|
$172.3m
+45.41%
|
$264.1m
+53.34%
|
$353.4m
+33.78%
|
$13.7m
-96.13%
|
$272.9m
+1895.34%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $762k | $11.3m | ($1.4m) | ($9.3m) | $90.6m | $106.7m | ($147.6m) | $221.1m | ($141.3m) | ($19.3m) | $336.6m | |
| Beginning Cash Position | — | — | — | — | — | — | $222.1m | $74.5m | $295.6m | $154.3m | $108.9m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $2.1m | $277k | $26k | $178k | $6.6m | $6.3m | $11.5m | $5.1m | $8.0m | $12.1m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | $1.6m | $2.0m | $2.1m | $0 | $0 | $13.2m | — | |
| Income Taxes Paid, Net | — | — | — | — | — | — | — | — | — | $150 | — | |
| Additional Financial Items | ||||||||||||
| Derivative, Gain (Loss) on Derivative, Net | — | — | — | — | — | $389k | $187k | $0 | $0 | — | — | |
| General and Administrative Expense | $13.3m | $15.9m | $17.3m | $16.1m | $22.5m | $25.2m | $33.3m | — | — | — | — | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | $433k | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $4.9m | $6k | — | |
| Investment Income, Interest | — | — | — | — | $841k | $403k | $5.9m | $21.2m | $26.1m | $22.7m | — | |
| Operating Expenses | $45.0m | $64.1m | $77.4m | $59.1m | $72.9m | $113.5m | $151.8m | $230.0m | $363.4m | $445.4m | — | |
| Operating Lease, Expense | — | — | — | $447k | $425k | $413k | $440k | $743k | $1.1m | $900k | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | — | $172.3m | $264.1m | $353.4m | $13.7m | $272.9m | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | — | ($186.2m) | $117.6m | ($219.8m) | $290.0m | $175.5m | |
| Change In Account Payable | — | — | — | — | — | — | ($1.3m) | $5.6m | $1.7m | $5.0m | ($12.5m) | |
| Change In Cash Supplemental As Reported | — | — | — | — | — | — | ($147.6m) | $221.1m | ($141.3m) | ($19.3m) | — | |
| Change In Other Working Capital | — | — | — | — | — | ($13.1m) | ($3.5m) | $10.7m | $12.0m | — | ($15.4m) | |
| Change In Payable | — | — | — | — | — | — | ($1.3m) | $5.6m | $1.7m | $5.0m | ($12.5m) | |
| Change In Prepaid Assets | — | — | — | — | — | — | ($3.0m) | $676k | ($8.4m) | ($14.5m) | ($538k) | |
| Changes In Cash | — | — | — | — | — | — | ($147.6m) | $221.1m | ($141.3m) | ($19.3m) | $227.7m | |
| End Cash Position | — | — | — | — | — | — | $74.5m | $295.6m | $154.3m | $135.0m | $336.6m | |
| Financing Cash Flow | — | — | — | — | — | — | $172.3m |
$264.1m
+53.34%
|
$353.4m
+33.78%
|
$13.7m
-96.13%
|
$272.9m
+1895.34%
|
|
| Free Cash Flow | — | — | — | — | — | — | ($133.7m) | ($160.6m) | ($274.9m) | ($323.2m) | ($220.9m) | |
| Gain Loss On Investment Securities | — | — | — | — | — | ($389k) | ($187k) | — | — | — | — | |
| Investing Cash Flow | — | — | — | — | — | — | ($186.2m) | $117.6m | ($219.8m) | $290.0m | $175.5m | |
| Net Investment Purchase And Sale | — | — | — | — | — | — | ($186.4m) | $117.6m | ($219.8m) | $290.2m | $175.7m | |
| Net PPE Purchase And Sale | — | — | — | — | — | — | $225k | $0 | $0 | ($187k) | ($227k) | |
| Operating Gains Losses | — | — | — | — | — | ($389k) | ($187k) | — | — | — | — | |
| Other Non Cash Items | — | — | — | — | — | — | $1.5m | $739k | $1.0m | $1.3m | — | |
| Proceeds From Stock Option Exercised | — | — | — | — | — | — | $11.9m | $6.0m | $9.7m | $13.7m | $29.0m | |
| Provisionand Write Offof Assets | — | — | — | — | — | — | — | $0 | $0 | $3.7m | $3.7m | |
| Purchase Of Investment | — | — | — | — | — | — | ($495.3m) | ($354.6m) | ($557.1m) | ($195.8m) | ($218.8m) | |
| Purchase Of PPE | $261k | $84k | $187k | $187k | $187k | $129k | $0 | $0 | $0 | ($187k) | ($187k) | |
| Sale Of Investment | — | — | — | — | — | — | $308.9m | $472.2m | $337.3m | $486.0m | $394.5m | |
| Sale Of PPE | — | — | — | — | — | $0 | $225k | $0 | $0 | — | $0 | |
| Stock Based Compensation | — | — | — | — | — | — | $16.0m | $31.0m | $43.0m | $47.5m | $49.4m |